An Australian perspective on clinical, economic and regulatory considerations in emerging nanoparticle therapies for infections.

ABSTRACT: Antimicrobial resistance (AMR) poses a growing global health threat. Nanomedicine, combined with drug repurposing, may help extend the effective lifespan of current and new antimicrobials. This review, presents an Australian perspective on nanotechnology-based therapies, highlighting scientific and clinical challenges. Early consideration of the potential barriers to market access may help to accelerate research translation, regulatory approval and patient access to nano-antimicrobial (NAM) drugs for resistant pathogens, not only in Australia, but globally.

SUBMITTER: Muir BW 

PROVIDER: S-EPMC11836273 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature